Skip to main content Skip to page footer

Our Platform

The ITCC-P4 platform is a sustainable, comprehensive preclinical drug testing platform in paediatric oncology. It is composed of four core components, to bring you the best expertise and capabilities.

Check our platform’s overview below and get in touch for more information. 

PDX models

In ITCC-P4, we provide the world´s largest repertoire of PDX models of paediatric tumours, available in one place and fully characterized.

We have built a large collection of patient derived xenografts (PDX) models across all relevant tumour entities, including high-risk, relapsed and rare cancers, well representing the paediatric cancer landscape. Each model has been fully characterized molecularly, pharmacologically, and clinically. This includes RNA & DNA sequencing as well as methylation profiling and in vivo treatment with standard-of-care drugs (+/- irradiation) and experimental drugs as well as combinations thereof. Our panel is being continuously enriched over time, with the in-licensing of new models (including immune-competent mouse models) and continuous improvement of their annotation and testing information.

Learn how to develop PDX models of cancer on humanized mouse models presented by Dr. Jens Hoffmann, Managing Director at EPO:

Learn about the relevance of our paediatric PDX model collection presented by Dr. Julia Schueler, Research Director & Therapeutic Area Lead at Charles River:

Academic experts

ITCC-P4’s world leading experts are immediately available to contribute paediatric oncology expertise to your project.

We leverage a panel of 30+ Paediatric Oncology experts with combined preclinical and clinical expertise and in-depth knowledge in specific tumour types. The experts can be involved in your project from start to end, to provide advice on the most suitable preclinical study design and models to use/entities to prioritize, as well as to perform the application-oriented biological and medical interpretation of your testing results, in conjunction with the molecular data.

Find out below where our experts come from.

P4 Database

ITCC-P4s unique omics and drug testing database reveals a comprehensive dataset of molecular phenotyping and pharmacological characterization corresponding to the original tumour material and respective PDX. 

The database is implemented on the R2 platform, a versatile online tool operated by Amsterdam UMC that allows any researcher to explore and analyze genomic data, without the need for bioinformatics or coding expertise. R2 is composed of a data warehouse that stores genomics data (such as gene expression, copy number mutation etc.), coupled to a suite of interactive tools that allows users to explore this information.

Dedicated tools and data are available for ITCC-P4 database that are instrumental in selecting PDX models for preclinical evaluation of your asset based on annotation, as well as molecular characterization. In addition, an online set of tools also provides an intuitive way to explore experimental in vivo data (both in terms of toxicity and efficacy) and connect those findings to the molecular data. Thereby the ITCC-P4 database can find crucial new insights on modes of action, as well as associations that could help to unravel important properties of your asset, e.g., biomarkers.  

Explore our PDX repertoire and learn more about our models and about their characteristics!



Three contract research organizations (CROs; Charles River Laboratories, EPO Berlin and XenTech) are contributing their long-lasting cutting-edge testing capabilities to conduct your preclinical drug testing experiments. 

Their combined capacities ensure the scalability of our platform, with high-level expertise, infrastructures, and SOP controlled approaches. All of them have an extensive track record in preclinical testing of oncology assets and leverage a diversified customer portfolio, from Big Pharma to small Biotechs, with an in-depth understanding of your specific needs.

Our platform can handle different experimental settings (e.g., single mouse trial, simple conventional study or complex conventional study, with either one or several tumour entities reflected in the PDX panel). Contact us for more information.